Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Seres Therapeutics, Inc. (MCRB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M | $143.9M | $11.9M | $27.2M | $26.9M | $32.1M | $21.8M | $0 | — | — |
| Research & development | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M | $90.6M | $80.1M | $96.0M | $89.5M | $82.0M | $38.1M | $10.7M | $4.8M |
| Operating expenses | $94.8M | $121.3M | $195.1M | $179.9M | $209.4M | $121.3M | $106.4M | $128.6M | $123.5M | $114.6M | $54.9M | $15.1M | $6.1M |
| Operating income | −$94.0M | −$121.3M | −$195.1M | −$179.9M | −$64.5M | −$88.1M | −$71.9M | −$100.3M | −$91.4M | −$92.8M | −$54.9M | −$15.1M | −$6.1M |
| EBITDAderived | −$89.8M | −$115.8M | −$188.9M | −$173.3M | −$58.5M | −$81.6M | −$64.3M | −$92.4M | −$84.1M | −$88.6M | −$54.1M | −$14.9M | −$6.0M |
| Net income | $5.7M | $136,000 | −$113.7M | −$250.2M | −$65.6M | −$89.1M | −$70.3M | −$98.9M | −$89.4M | −$91.6M | −$54.8M | −$16.7M | −$6.1M |
| Basic EPSper diluted share | $0.64 | $0.00 | -$17.77 | -$2.31 | -$0.72 | -$1.12 | -$1.24 | -$2.43 | -$2.21 | -$2.30 | -$2.33 | -$2.67 | -$1.09 |
| Diluted EPSper diluted share | $0.64 | $0.00 | -$17.77 | -$2.31 | -$0.72 | -$1.12 | -$1.24 | -$2.43 | -$2.21 | -$2.30 | -$2.33 | -$2.67 | -$1.09 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 · 10b5-1 | Shaff Eric D.Director | SellCommon Stock | 259 | $7.53 | $2.0K | 12.0K |
| May 18, 2026Form 4 | Brady KellySee Remarks | SellCommon Stock | 59 | $7.53 | $444.27 | 8.6K |
| May 18, 2026Form 4 · 10b5-1 | DesRosier ThomasSee Remarks | SellCommon Stock | 79 | $7.53 | $594.87 | 8.0K |
| May 18, 2026Form 4 · 10b5-1 | Henn Matthew RSee Remarks | SellCommon Stock | 77 | $7.53 | $579.81 | 7.8K |
| Feb 15, 2026Form 4 · 10b5-1 | Young Teresa L.See Remarks | SellCommon Stock | 75 | $8.47 | $635.25 | 8.6K |